Fortress to get NIH funding for trial of Triplex vaccine to prevent CMV in liver transplant patients

Aug. 11, 2022 9:26 AM ETFortress Biotech, Inc. (FBIO)By: Ravikash, SA News Editor

Modern Medicine Research Laboratory: Diverse Team of Multi-Ethnic Young Scientists Passes Samples in Petri Dish. Advanced Lab with High-Tech Equipment, Microbiology Researchers Design, Develop Drugs


  • Fortress Biotech (NASDAQ:FBIO) said that its cytomegalovirus (CMV) vaccine Triplex received a grant from the National Institute of Allergy and Infectious Diseases (NIAID) which could provide over $20M in non-dilutive funding.
  • The award by NIAID, part of the National Institutes of Health (NIH) will fund a phase 2 trial of Triplex — being developed by Fortress' unit Helocyte — for control of CMV in patients undergoing liver transplantation.
  • CMV is a common virus which is asymptomatic in healthy individuals, but can cause infection in pregnant women who then can pass the virus to their babies. CMV can be severe and life-threatening for those with weakened immune systems and those undergoing cell and solid organ transplant.
  • Helocyte secured an exclusive worldwide license to Triplex in 2015 from City of Hope, the developer of the vaccine.
  • Helocyte's other CMV vaccine ConVax is aimed to prevent transmission of CMV, particularly from mother to fetus, Fortress noted.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.